Trial Profile
A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Imatinib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 20 Jan 2021 Status changed from active, no longer recruiting to completed.
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Jul 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2016.